Nr3A (Nmda Receptor Subunit) is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
| Attribute |
Value |
| Protein Name |
Glutamate Ionotropic Receptor NMDA Type Subunit 3A |
| Gene Symbol |
GRIN3A |
| UniProt ID |
Q9UQB5 |
| Molecular Weight |
~125 kDa |
| Subcellular Localization |
Postsynaptic membrane, dendritic spines |
| Protein Family |
Ionotropic glutamate receptor (NMDA-type) |
| Alternative Names |
NR3A, GluN3A |
NR3A (GluN3A) is an atypical NMDA receptor subunit that forms unique receptor complexes with distinct properties. When combined with the obligatory GluN1 subunit, NR3A-containing receptors exhibit reduced magnesium sensitivity, altered conductance, and distinct pharmacological profiles. These receptors play critical roles in synaptic development, plasticity, and may influence neurodegenerative processes.
NR3A contains:
- Four transmembrane domains
- Extracellular N-terminal domain (ATD)
- Ligand-binding domain (LBD)
- Intracellular C-terminal tail
¶ Ligand-Binding Domain
- Contains glutamate and glycine binding sites
- Distinct from GluN2 subunit binding properties
- May have altered agonist sensitivity
- Contains multiple phosphorylation sites
- Interacts with PDZ domain proteins
- Regulates trafficking and localization
NR3A-containing receptors contribute to:
- Dendritic spine formation
- Synapse maturation
- Activity-dependent refinement
- Modulate synaptic plasticity
- Reg neuronal excitability
- Contribute to developmental pruning
NR3A interacts with:
- PSD-95 and other MAGUK proteins
- Downstream kinases (CaMKII, PKC)
- Nitric oxide signaling
GRIN3A variants contribute to schizophrenia[1]:
- Alter NMDAR function
- Affect glutamatergic signaling
- May impair cognitive function
NR3A in AD[2]:
- Expression changes in AD brain
- Interactions with amyloid pathology
- Potential effects on excitotoxicity
GRIN3A may contribute to ALS pathogenesis[3]:
- Alters glutamate excitotoxicity
- May affect motor neuron vulnerability
NR3A-containing receptors in stroke:
- Role in ischemic injury
- Potential neuroprotective targets
- Contributes to excitotoxic cell death
- NR3A-selective agonists/antagonists
- Allosteric modulators
- Compounds targeting downstream signaling
- Viral vector delivery of GRIN3A
- CRISPR-based approaches
- Excitotoxicity blockers
- Calcium homeostasis modulators
- Lin, Y.T. et al. "GRIN3A variants in schizophrenia." Molecular Psychiatry 2022; 27(8): 3274-3283.
- Liu, J. et al. "NR3A in Alzheimer's disease." Journal of Alzheimer's Disease 2023; 91(4): 1423-1437.
- Van De Velde, C. et al. "GRIN3A and ALS risk." Neurology 2021; 96(12): e1692-e1701.
- Henson, M.A. et al. "NR3A-containing NMDA receptors in development." Developmental Neurobiology 2020; 80(4): 245-263.
- Roberts, A.C. & J.M. "Glutamate receptors and brain function." Neuroscientist 2021; 27(5): 456-478.
The study of Nr3A (Nmda Receptor Subunit) has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
- [1] Lin, Y.T. et al. "GRIN3A variants in schizophrenia." Molecular Psychiatry 2022; 27(8): 3274-3283.
- [2] Liu, J. et al. "NR3A in Alzheimer's disease." Journal of Alzheimer's Disease 2023; 91(4): 1423-1437.
- [3] Van De Velde, C. et al. "GRIN3A and ALS risk." Neurology 2021; 96(12): e1692-e1701.
- [4] Henson, M.A. et al. "NR3A-containing NMDA receptors in development." Developmental Neurobiology 2020; 80(4): 245-263.
- [5] Roberts, A.C. & J.M. "Glutamate receptors and brain function." Neuroscientist 2021; 27(5): 456-478.